NasdaqCM - Nasdaq Real Time Price USD

Mangoceuticals, Inc. (MGRX)

0.2280 -0.0054 (-2.31%)

At close: November 2 at 4:00:00 PM EST

0.2424 +0.0144 (+6.32%)

Pre-Market: 7:51:30 AM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets

GlobeNewswire 2mo ago

MGRX
+6.32%
Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor

TMX Newsfile 3mo ago

MGRX
+6.32%
Top Midday Decliners

PREMIUM
MT Newswires 10mo ago

MGRX
+6.32%
NKE

LW
Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim

Pharmaceutical Technology 11mo ago

LLY

MGRX
+6.32%
NOVO-B.CO
Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close

GlobeNewswire 24d ago

MGRX
+6.32%
Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

GlobeNewswire 2mo ago

MGRX
+6.32%
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination

GlobeNewswire 2mo ago

MGRX
+6.32%
Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

GlobeNewswire 3mo ago

MGRX
+6.32%
BC-Most Active Stocks

Associated Press Finance 7mo ago

NVDA

FFAI

MGRX
+6.32%
Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

GlobeNewswire 7mo ago

MGRX
+6.32%
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

GlobeNewswire 7mo ago

MGRX
+6.32%
Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

GlobeNewswire 8mo ago

MGRX
+6.32%

Performance Overview

Return	MGRX	S&P 500 (^GSPC)
YTD	-69.19%	+10.17%
1-Year	-89.04%	+10.25%
3-Year	-97.38%	+74.66%

U.S. markets open in 22m

Mangoceuticals, Inc. (MGRX)

Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets

Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor

Top Midday Decliners

Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim

Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close

Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination

Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

BC-Most Active Stocks

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study